Chemotherapeutic drug screening in 3D-Bioengineered human myobundles provides insight into taxane-induced myotoxicities.

dc.contributor.author

Torres, Maria J

dc.contributor.author

Zhang, Xu

dc.contributor.author

Slentz, Dorothy H

dc.contributor.author

Koves, Timothy R

dc.contributor.author

Patel, Hailee

dc.contributor.author

Truskey, George A

dc.contributor.author

Muoio, Deborah M

dc.date.accessioned

2022-11-07T14:21:10Z

dc.date.available

2022-11-07T14:21:10Z

dc.date.issued

2022-10

dc.date.updated

2022-11-07T14:21:00Z

dc.description.abstract

Two prominent frontline breast cancer (BC) chemotherapies commonly used in combination, doxorubicin (DOX) and docetaxel (TAX), are associated with long-lasting cardiometabolic and musculoskeletal side effects. Whereas DOX has been linked to mitochondrial dysfunction, mechanisms underlying TAX-induced myotoxicities remain uncertain. Here, the metabolic and functional consequences of TAX ± DOX were investigated using a 3D-bioengineered model of adult human muscle and a drug dosing regimen designed to resemble in vivo pharmacokinetics. DOX potently reduced mitochondrial respiratory capacity, 3D-myobundle size, and contractile force, whereas TAX-induced acetylation and remodeling of the microtubule network led to perturbations in glucose uptake, mitochondrial respiratory sensitivity, and kinetics of fatigue, without compromising tetanic force generation. These findings suggest TAX-induced remodeling of the microtubule network disrupts glucose transport and respiratory control in skeletal muscle and thereby have important clinical implications related to the cardiometabolic health and quality of life of BC patients and survivors.

dc.identifier

S2589-0042(22)01461-4

dc.identifier.issn

2589-0042

dc.identifier.issn

2589-0042

dc.identifier.uri

https://hdl.handle.net/10161/26223

dc.language

eng

dc.publisher

Elsevier BV

dc.relation.ispartof

iScience

dc.relation.isversionof

10.1016/j.isci.2022.105189

dc.subject

Bioengineering

dc.subject

Biological sciences

dc.subject

Cancer

dc.subject

Pharmacology

dc.title

Chemotherapeutic drug screening in 3D-Bioengineered human myobundles provides insight into taxane-induced myotoxicities.

dc.type

Journal article

duke.contributor.orcid

Koves, Timothy R|0000-0001-8763-5866

duke.contributor.orcid

Truskey, George A|0000-0002-6885-4489

duke.contributor.orcid

Muoio, Deborah M|0000-0003-3760-9277

pubs.begin-page

105189

pubs.issue

10

pubs.organisational-group

Duke

pubs.organisational-group

Pratt School of Engineering

pubs.organisational-group

School of Medicine

pubs.organisational-group

Basic Science Departments

pubs.organisational-group

Clinical Science Departments

pubs.organisational-group

Institutes and Centers

pubs.organisational-group

Pharmacology & Cancer Biology

pubs.organisational-group

Biomedical Engineering

pubs.organisational-group

Medicine

pubs.organisational-group

Medicine, Endocrinology, Metabolism, and Nutrition

pubs.organisational-group

Medicine, Geriatrics

pubs.organisational-group

Duke Cancer Institute

pubs.organisational-group

Institutes and Provost's Academic Units

pubs.organisational-group

University Institutes and Centers

pubs.organisational-group

Duke Molecular Physiology Institute

pubs.organisational-group

Sarah Stedman Nutrition & Metabolism Center

pubs.organisational-group

Center for the Study of Aging and Human Development

pubs.organisational-group

Initiatives

pubs.organisational-group

Duke Science & Society

pubs.organisational-group

Nicholas Institute-Energy Initiative

pubs.organisational-group

Regeneration Next Initiative

pubs.publication-status

Published

pubs.volume

25

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Chemotherapeutic drug screening in 3D-Bioengineered human myobundles provides insight into taxane-induced myotoxicities.pdf
Size:
5.96 MB
Format:
Adobe Portable Document Format
Description:
Accepted version